Drugs in R&D

Papers
(The H4-Index of Drugs in R&D is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Trametinib Sensitivity is Defined by a Myeloid Differentiation Profile in Acute Myeloid Leukemia36
Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD924
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes22
Chinese- and French-Manufactured Immediate-Release Glucophage® Bioequivalence: A Randomized, Open-Label, Crossover Study21
Comparative Efficacy of Different Drugs for the Treatment of Dilated Cardiomyopathy: A Systematic Review and Network Meta-analysis21
Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis19
The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process17
Novel Strategies for the Treatment of COVID-1915
Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation14
Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease13
Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications13
The Pitfalls of Abnormal Laboratory Value Interpretation in Vaccine Clinical Trials: The Example of Asymptomatic Transient Neutropenia12
0.20472097396851